Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37,038 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.
Niu N, Qiu F, Xu Q, He G, Gu X, Guo W, Zhang D, Li Z, Zhao Y, Li Y, Li K, Zhang H, Zhang P, Huang Y, Zhang G, Han H, Cai Z, Li P, Xu H, Chen G, Xue J, Jiang X, Jahromi AH, Li J, Zhao Y, de Faria Castro Fleury E, Huo S, Li H, Jerusalem G, Tripodi D, Liu T, Zheng X, Liu C. Niu N, et al. Among authors: zhang p, zhang g, zhang d, zhang h. Nat Commun. 2022 Nov 17;13(1):7043. doi: 10.1038/s41467-022-34838-w. Nat Commun. 2022. PMID: 36396665 Free PMC article. Clinical Trial.
Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Zhang L, Wu ZY, Li J, Lin Y, Liu Z, Cao Y, Zhang G, Gao HF, Yang M, Yang CQ, Zhu T, Cheng MY, Ji F, Li J, Wang K. Zhang L, et al. Among authors: zhang g. Int J Cancer. 2022 Feb 15;150(4):654-662. doi: 10.1002/ijc.33830. Epub 2021 Oct 7. Int J Cancer. 2022. PMID: 34591977 Free article. Clinical Trial.
Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
Zhang L, Wu Z, Li J, Zhu D, Yang L, Shao Y, Lin Y, Liu Z, Cao Y, Zhang G, Shang S, Zhang Y, Wang K. Zhang L, et al. Among authors: zhang g, zhang y. JCO Precis Oncol. 2023 Jan;7:e2200337. doi: 10.1200/PO.22.00337. JCO Precis Oncol. 2023. PMID: 36652665 Clinical Trial.
Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial.
Gao HF, Wu Z, Lin Y, Song XY, Cao Y, Chen QJ, Zhang G, Fu P, Liu Z, Zhang LL, Yang CQ, Yang M, Zhu T, Ji F, Li JQ, Cheng MY, Wang K. Gao HF, et al. Among authors: zhang g, zhang ll. Ther Adv Med Oncol. 2021 Apr 20;13:17588359211009003. doi: 10.1177/17588359211009003. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33959195 Free PMC article.
Multi-Omics profiling identifies aldehyde dehydrogenase 2 as a critical mediator in the crosstalk between Treg-mediated immunosuppression microenvironment and hepatocellular carcinoma.
Liu ZY, Lin XH, Guo HY, Shi X, Zhang DY, Sun JL, Zhang GC, Xu RC, Wang F, Yu XN, Wang D, Weng SQ, Shen XZ, Liu TT, Dong L, Zhu JM. Liu ZY, et al. Among authors: zhang gc. Int J Biol Sci. 2024 May 5;20(7):2763-2778. doi: 10.7150/ijbs.93075. eCollection 2024. Int J Biol Sci. 2024. PMID: 38725845 Free PMC article.
37,038 results
You have reached the last available page of results. Please see the User Guide for more information.